Avaí Bio Secures Cell Supplier for Diabetes Therapy, Advancing Encapsulation Approach
Event summary
- Avaí Bio and Austrianova reached an agreement in principle with an undisclosed partner to supply insulin-producing cells for their Insulinova diabetes therapy.
- The deal is subject to definitive agreements and customary closing conditions, expected to complete in the coming days.
- Insulinova combines cell-programmed insulin-producing cells with Austrianova's Cell-in-a-Box® encapsulation technology.
- Vertex Pharmaceuticals has shown promising results in its stem-cell-derived islet therapy trials, validating the approach Avaí Bio is pursuing.
The big picture
Avaí Bio's agreement with a cell supplier marks a critical step in advancing its diabetes therapy, which aims to provide an alternative to insulin injections. The broader field is heating up, with multiple companies pursuing cell-based therapies for diabetes, each taking different approaches to solving the challenges of cell production and immune protection.
What we're watching
- Execution Risk
- Whether Avaí Bio can successfully close the definitive agreements and secure the cell supply as planned.
- Competitive Dynamics
- How Insulinova's encapsulation approach will differentiate it from competitors like Vertex Pharmaceuticals and Sernova Biotherapeutics.
- Regulatory Pathway
- The pace at which Avaí Bio can advance Insulinova through preclinical development and into clinical trials.
Related topics